In this study, patients with a history of myocardial infarction (MI) and elevated levels of high-sensitivity C-reactive protein (hs-CRP) (≥2 mg/dl) were randomly assigned to receive either canakinumab [an interleukin-1β (IL-1β) monoclonal antibody] or placebo. Here, IL1B is linked to myocardial infarction.